Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
Would you order an OncoType DX test on a <50 year old woman with T2 N1mi HR+ HER2- breast cancer?
Answer from: Medical Oncologist at Community Practice
Yes. The patient will need chemotherapy as per RxPonder Trial.
Comments
Medical Oncologist at Hollywood Private Hospital
Is this correct? The protocol of RxPonder states-&...
Medical Oncologist at Los Angeles VA Medical Center
For micrometastases and how to interpret, please s...
7816
7819
Sign in or Register to read more
11847
Related Questions
Would you give adjuvant TDM-1 to a patient with HER2-positive breast cancer s/p NAC with TCHP found to have no residual disease in the breast, but presence of ITCs ypN0(i+) in one axillary lymph node?
Do you hold endocrine therapy during adjuvant breast radiotherapy?
What neoadjuvant chemotherapy do you suggest for a rapidly growing triple-negative breast cancer?
Is there data to support the substitution of docetaxel with nab-paclitaxel in the TCHP neoadjuvant regimen in the event of hypersensitivity?
What recommendations would you make for a patient on long-term phenytoin due to epilepsy with a newly diagnosed breast cancer requiring doxorubicin as part of her chemotherapy?
Does delay to the time of lumpectomy impact your decision to omit radiation?
Would you recommend adjuvant endocrine therapy in combination with immunotherapy for triple negative metaplastic breast cancer with residual disease that is ER strongly positive?
How would you approach the treatment of low grade, stage IA, triple negative apocrine adenocarcinoma of the breast in a female patient in her 70s?
With the recent FDA approval of adjuvant ribociclib, how are you deciding between ribociclib and abemaciclib for high risk HR+/HER2− early breast cancer?
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?
Is this correct? The protocol of RxPonder states-&...
For micrometastases and how to interpret, please s...